1121 E Broadway Street
Inimmue is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation and immunology. Our pipeline currently includes several compounds and formulations thereof that modulate the innate immune system through Toll-like Receptors 4 and 7/8. Current preclinical programs are developing these assets for use in areas of critical patient need such as food allergy, allergic rhinitis, autoimmunity, as well as topically in cancer. Additionally, Inimmune applies its collective 50 years of expertise in preclinical drug development to offer various contract services, see SERVICES for more info on this.
President and CEO: Jay T. Evans, Ph.D.
COO: David J. Burkhart, Ph.D.
Vice President, Early Discovery: Helene Bazin-Lee, Ph.D
Vice President, Manufacturing and Dev.: Kendal Ryter, Ph.D.
Director of Immunology: Alyson Smith, Ph.D
Please click here for Inimmue's job opportunities.
Please click here for Inimmue's pipeline.